Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company: Theranexus & Pherecydes-Pharma POCs
  • 2016: INTERVIEW: "Drug Discovery and health Big Data. The enormous Bubble will explode.” Manuel GEA, CEO of BMSystems in Biotech & Finances the leading biotech sector information letter
  • 2016: ANNOUNCEMENT: October 25, 2016: Discover why and how some CEOs and R&D managers have already launched “Fully External B plans” to de-risk their business and generate unexpected opportunities.

  • 2016: PRESS-RELEASE: Paris October 4, 2016: Theranexus, a CEA Life Sciences' spin-off exploiting CEA/BMSystems' copatent WO/2010/029131, obtained an orphan drug designation from the FDA for THN102, (in Phase II)  in the treatment of narcolepsy. Download  the official Theranexus' press-relase

  • 2016: ANNOUNCEMENT: Paris October 5, 2016: BMSystems' CEO invited to present its digital-biology strategy and achievements at the inaugural session of Medicen Paris Region 10th years anniversary

  • 2016: PRESS RELEASE: Paris September 5, 2016: BMSystems selected to present CADI Discovery at the Connexion R&D conference organized by COSMETIC-VALLEY the leading Perfumery & Cosmetic cluster in France.

  • 2016: ANNOUNCEMENT August 1, 2016: BIO-MODELING SYSTEMS' novel Parkinson's therapy mentioned in a Report Covering 179 Companies. A new recognition of CADI Discovery capability to generate novel therapeutic strategies in complex human diseases of which CNS
  • 2016: ANNOUNCEMENT : May 31, 2016: Theranexus, CEA Life Sciences' spin-off exploiting CEA/BMSystems' copatent WO/2010/029131, in CNS therapies in Biotech Info (page 11)

  • 2016: Updated: Inaugural Presentation Bio-Entrepreneur 2015: The future will be digital and biology, but who will lead? Google? Watson? Alone or MDs, Physiologists, Biologists educating and mastering them combining diagnostics, therapies, connected devices and IT technologies?

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology company that delivers

"Correct understanding of life mechanisms makes novel integrated diagnostics, therapies & preventive solutions discovery smarter, faster & cheaper for healthcare, diagnostic, health technologies, nutrition, and cosmetics!"

Bio-Modeling Systems is the world’s first Mechanisms-Based medicine company that changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data to generate validated & directly exploitable first in class heuristic non-mathematical mechanistic CADI™ models.

Created in 2004, profitable since 2006, thanks to our recurrent clients, our robust decision-making support & discoveries already led to:

  1. A world's first in neurodegenerative diseases (publication) with CEA: 2 awards in the US & Europe

  2. Pherecydes-Pharma: BMSystems' spin-off, MR infections therapies,  3 patents, publication, world's first clinical multi-centric trial with bacteriophages in Phase I/II,

  3. Theranexus: the CEA Life Sciences' spin-off exploiting  CEA/BMSystems' copatent  WO/2010/029131, in CNS therapies,  Phase II entry,  ODD from FDA, and

  4. Due to a failure rate of 90%-95%, our critical and high impact "robust decision-making" support for CEOs, R&D or Business managers and Investors: GO-NO GO decision before acquisition or next phase, and R&D Rescue, External R&D “B plan”, & Exploratory Discovery programs.

We warmly invite you to download our  6 pages management summary,  our Short corporate Presentation or our Full Presentation with all non-confidential details of our 10 POCs.

The life-modeling issue


BMSystems’ solutions to critical & high impact R&D and business issues

Invented and operated by our Biologists, CADI™* Discovery is, since 2004, the world's first and only to date operational "Mechanisms-based Medicine" platform that proposes:

  1. robust decision making support for R&D and Business, and

  2. the discovery of cost-effective lower risk patentable novel integrated solutions,

*CADI™ : Computer Assisted Deductive Integration